Article Details

Turn Bio inks $300m epigenetic reprogramming deal with HanAll Biopharma

Retrieved on: 2024-05-28 16:12:01

Tags for this article:

Click the tags to see associated articles and topics

Turn Bio inks $300m epigenetic reprogramming deal with HanAll Biopharma. View article details on hiswai:

Excerpt

Longevity biotech Turn Biotechnologies today announced it has signed an exclusive global licensing agreement with Korean pharma giant HanAll Biopharma ...

Article found on: longevity.technology

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up